131 related articles for article (PubMed ID: 32861463)
1. Tumour markers and their utility in imaging of abdominal and pelvic malignancies.
Lahoud RM; O'Shea A; El-Mouhayyar C; Atre ID; Eurboonyanun K; Harisinghani M
Clin Radiol; 2021 Feb; 76(2):99-107. PubMed ID: 32861463
[TBL] [Abstract][Full Text] [Related]
2. Tumor markers: myths and facts unfolded.
Faria SC; Sagebiel T; Patnana M; Cox V; Viswanathan C; Lall C; Qayyum A; Bhosale PR
Abdom Radiol (NY); 2019 Apr; 44(4):1575-1600. PubMed ID: 30498924
[TBL] [Abstract][Full Text] [Related]
3. Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers.
Desai S; Guddati AK
World J Oncol; 2023 Feb; 14(1):4-14. PubMed ID: 36895994
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of serum carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), carbohydrate antigen 15-3 (CA15-3), alpha-fetoprotein (AFP) and human chorionic gonadotropin (hCG) levels in determining the malignancy of solitary pulmonary nodules.
Bekci TT; Senol T; Maden E
J Int Med Res; 2009; 37(2):438-45. PubMed ID: 19383238
[TBL] [Abstract][Full Text] [Related]
5. Review of Commonly Used Serum Tumor Markers and Their Relevance for Image Interpretation.
Reiter MJ; Costello JE; Schwope RB; Lisanti CJ; Osswald MB
J Comput Assist Tomogr; 2015; 39(6):825-34. PubMed ID: 26248153
[TBL] [Abstract][Full Text] [Related]
6. Interlaboratory surveys of the determination of tumour markers scatter and repeatability of the results.
Kruse R; Geilenkeuser WJ; Röhle G
Eur J Clin Chem Clin Biochem; 1993 Mar; 31(3):139-46. PubMed ID: 7683915
[TBL] [Abstract][Full Text] [Related]
7. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC, and CA 19-9 for monitoring transitional cell carcinoma of the bladder.
Pectasides D; Bafaloucos D; Antoniou F; Gogou L; Economides N; Varthalitis J; Dimitriades M; Kosmidis P; Athanassiou A
Am J Clin Oncol; 1996 Jun; 19(3):271-7. PubMed ID: 8638540
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.
Webb A; Scott-Mackie P; Cunningham D; Norman A; Andreyev J; O'Brien M; Bensted J
Ann Oncol; 1995 Jul; 6(6):581-7. PubMed ID: 8573538
[TBL] [Abstract][Full Text] [Related]
9. [Clinical usefulness of circulating tumor markers].
Ohkura H
Gan To Kagaku Ryoho; 2004 Jul; 31(7):1131-4. PubMed ID: 15272600
[TBL] [Abstract][Full Text] [Related]
10. Clinical application of tumour markers: a review.
Amayo AA; Kuria JG
East Afr Med J; 2009 Dec; 86(12 Suppl):S76-83. PubMed ID: 21591514
[TBL] [Abstract][Full Text] [Related]
11. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
12. Clinical use of tumor markers in oncology.
Jacobs EL; Haskell CM
Curr Probl Cancer; 1991; 15(6):299-360. PubMed ID: 1760927
[TBL] [Abstract][Full Text] [Related]
13. Letter from the Guest Editors.
Ram R; Pandey T
Semin Ultrasound CT MR; 2020 Apr; 41(2):121. PubMed ID: 32446426
[No Abstract] [Full Text] [Related]
14. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer.
Carpelan-Holmström M; Haglund C; Lundin J; Alfthan H; Stenman UH; Roberts PJ
Br J Cancer; 1996 Sep; 74(6):925-9. PubMed ID: 8826859
[TBL] [Abstract][Full Text] [Related]
15. Re: Tumour markers and their utility in imaging of abdominal and pelvic malignancies.
Wiles R; Taylor S
Clin Radiol; 2021 Jun; 76(6):466. PubMed ID: 33832701
[No Abstract] [Full Text] [Related]
16. Serum tumor markers.
Perkins GL; Slater ED; Sanders GK; Prichard JG
Am Fam Physician; 2003 Sep; 68(6):1075-82. PubMed ID: 14524394
[TBL] [Abstract][Full Text] [Related]
17. CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer.
Carpelan-Holmström M; Louhimo J; Stenman UH; Alfthan H; Järvinen H; Haglund C
Tumour Biol; 2004; 25(5-6):228-34. PubMed ID: 15627885
[TBL] [Abstract][Full Text] [Related]
18. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.
Sturgeon CM; Duffy MJ; Stenman UH; Lilja H; Brünner N; Chan DW; Babaian R; Bast RC; Dowell B; Esteva FJ; Haglund C; Harbeck N; Hayes DF; Holten-Andersen M; Klee GG; Lamerz R; Looijenga LH; Molina R; Nielsen HJ; Rittenhouse H; Semjonow A; Shih IeM; Sibley P; Sölétormos G; Stephan C; Sokoll L; Hoffman BR; Diamandis EP;
Clin Chem; 2008 Dec; 54(12):e11-79. PubMed ID: 19042984
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers in biological fluids associated with pregnancy.
Sarandakou A; Protonotariou E; Rizos D
Crit Rev Clin Lab Sci; 2007; 44(2):151-78. PubMed ID: 17364691
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of carcinoembryonic antigen, alpha fetoprotein, carbohydrate antigen 125 and carbohydrate antigen 19-9 in gastroenteropancreatic neuroendocrine neoplasms].
Chen L; Zhang Y; Chen M; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1002-1008. PubMed ID: 28900990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
